Your selection
NoneFilter by content type
Filter by content year
Filter by form group
Filter by type
Filter by tags
Filter by gallery
Filter by category
Filter by category
Filter by category
Filter by category
Statement: Biogen Provides Update on Parkinson’s Disease Clinical Development Program
June 5, 2023 - … disease; the potential of Biogen’s commercial business and pipeline programs; Biogen’s strategy and plans; the potential … disease; the potential of Biogen’s commercial business and pipeline programs; Biogen’s strategy and plans; the potential … disease; the potential of Biogen’s commercial business and pipeline programs; Biogen’s strategy and plans; the potential …
Biogen Announces Webcast of Annual Meeting of Stockholders
June 1, 2023 - … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, …
Biogen to Participate in the Jefferies Healthcare Conference
May 23, 2023 - … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, …
EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER’S DISEASE IN GREAT BRITAIN
May 21, 2023 - … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … Eisai; the potential of Biogen’s commercial business and pipeline programs, including lecanemab; and risks and … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, …
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease
May 15, 2023 - … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … Eisai; the potential of Biogen’s commercial business and pipeline programs, including lecanemab; and risks and … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, …
Biogen Announces Publication of BIIB080 Phase 1b Data in Nature Medicine
April 28, 2023 - … Disease by advancing Biogen’s industry-leading Alzheimer's pipeline across therapeutic modalities and molecular targets. … Disease by advancing Biogen’s industry-leading Alzheimer's pipeline across therapeutic modalities and molecular targets. … Disease by advancing Biogen’s industry-leading Alzheimer's pipeline across therapeutic modalities and molecular targets. …
FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS
April 25, 2023 - … endpoints. In addition to QALSODY, the company has a pipeline of investigational drugs being evaluated in ALS, … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … of ALS; the potential of our commercial business and pipeline programs, including QALSODY; and risks and …
Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta
April 12, 2023 - … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … disease; the potential of Biogen’s commercial business and pipeline programs; Biogen’s strategy and plans; the potential … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, …
BIOGEN TO REPORT FIRST QUARTER 2023 FINANCIAL RESULTS APRIL 25, 2023
April 11, 2023 - … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, …
Biogen Appoints Adam Keeney as Head of Corporate Development
April 4, 2023 - … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … and plans and the potential of our commercial business and pipeline programs; capital allocation and investment … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, …
